Entity

Time filter

Source Type

Moscow, Russia

Shamonov N.A.,LLC Pharmapark | Zyrianov D.A.,LLC Pharmapark | Selishchev S.V.,LLC Pharmapark | Orlova1 N.V.,LLC Pharmapark | Khamitov R.A.,LLC Pharmapark
Russian Journal of Biopharmaceuticals | Year: 2014

In this article we investigated pegylation process of recombinant interferon alfa-2a at the stage of the conjugation reaction. We offered mechanism for increasing the yield of the reaction by using an organic solvent (DMSO) as a component of the reaction buffer. It has been demonstrated that the addition of DMSO to a concentration of 30 % can increase the reaction yield by 40 % without changing the composition of the isoform formulation. To analyze the results of pegylation reaction we used the following analytical techniques: high performance liquid chromatography (ion exchange and gel permeation). © 2014 Folium Ltd. All rights reserved.


Shamonov N.A.,LLC Pharmapark | Zyrianov D.A.,LLC Pharmapark | Selishchev S.V.,LLC Pharmapark | Orlova N.V.,LLC Pharmapark | And 2 more authors.
Russian Journal of Biopharmaceuticals | Year: 2015

In this article we demonstrated a new method for producing monopegylated interferon alpha-2b without N-terminal isoform, possessing a low antiviral activity. The idea of the proposed method: the pegylation process we subjected the precursor of interferon alpha-2b, which is a fusion protein consisting of one molecule SUMOl yeast protein and one molecule of interferon alpha-2b. The pegylated precursor was further proteolysis with specific to the protein SUMOl ULP proteinase. After proteolysis and further purification we received monopegylated interferon al-pha-2b without N-terminal isoform. © 2015, Folium Ltd. All rights reserved.

Discover hidden collaborations